secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2026-05-14T20:17:07+00:00
Accession:  0001193125-26-224080
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx Q1 revenue $563K (+136% QoQ); net loss $3.5M; reaffirms FY revenue guidance $3-4M
--------------------------------------------------------------------------------

- Revenue $563,000, up 136% from Q4 2025; exceeds 50% of total FY2025 revenue.
- Net loss $3.5M vs $2.4M a year ago; cash $12.4M with runway into H2 2027.
- Active commercial cancer centers grew to 16 from 8 at year-end 2025; target 36 by year-end 2026.
- Phase III TIGeR-PaC enrollment at 106 of 114 patients (93%); full enrollment expected by June 2026.
- FY 2026 revenue guidance reaffirmed at $3-4 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/0001193125-26-224080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000119312526224080/rnxt-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer